Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries
详细信息 查看全文
- 作者：Victoria Divino (1)
Mitch DeKoven (1)
Shawn Hallinan (1)
Nebibe Varol (2)
Sara Bruce Wirta (3)
Won Chan Lee (1)
Matthew Reaney (2) - 关键词：Databases ; Diabetes mellitus ; Exenatide BID ; Exenatide QW ; Glucagon ; like peptide 1 ; Liraglutide ; Retrospective studies ; Treatment outcome ; Type 2/drug therapy
- 刊名：Diabetes Therapy
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：5
- 期：2
- 页码：499-520
- 全文大小：1,139 KB
- 参考文献：1. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels: International Diabetes Federation; 2013. http://www.idf.org/diabetesatlas. Accessed February 18, 2014.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-9. CrossRef
3. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med. 2014;370:794-. CrossRef
4. Byetta: EPAR—European Medicines Agency—Europa, European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/000698/WC500051845.pdf (2011). Accessed March 28, 2013.
5. Victoza: EPAR—Product Information—European Medicines Agency. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/001026/WC500050017.pdf (2014). Accessed October 21, 2014.
6. European Medicines Agency: Assessment report for Victoza. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf. Accessed September 16, 2013.
7. Type 2 Diabetes—newer agents (partial update of CG66) (CG87): NICE clinical guidelines. http://publications.nice.org.uk/type-2-diabetes-cg87 (2009). Accessed February 20, 2013.
8. Bydureon : EPAR—Product information—European Medicines Agency. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf (2011). Accessed March 12, 2013.
9. GLP-1-agonisten: MedicijnBalans. http://medicijnbalans.nl/medicijngroepen/diabetes-type-2/middel/99 (2014). Accessed October 21, 2014.
10. National Guidelines for Diabetes Care—summary. Socialstyrelsen. http://www.socialstyrelsen.se/nationalguidelines/nationalguidelinesfordiabetescare (2010). Accessed February 12, 2014.
11. Scheen AJ, Van Gaal LF. Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes. Rev Med Liege. 2010;65:464-0.
12. McDonell A, Zammit DC, Haslam T, et al. PDB35 estimating the real life daily usage and daily cost of GLP-1 receptor agonists in the UK setting. Value Health. 2011;14:A477-. CrossRef
13. Miller LA, Burudpakdee C, Zagar A, et al. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany. J Med Econ. 2012;15:746-7. CrossRef
14. Fuchs S, Kostev L, Seitz L, Wohlleben M. Ermittlung der tats?chlichen Tagesdosierung von Liraglutid (PDD) unter realen Versorgungsbedingungen im Hinblick auf die Berechnung von Tagestherapiekosten. Diabetologie und Stoffwechsel. 2011;6:P234.
15. Buitenhuis R. Impact of a restrictive reimbursement policy on access, costs and quality and safety of treatment: Analysis of a Dutch reimbursement case regarding GLP-1 therapy. Masters thesis, Erasmus University, Rotterdam. http://thesis.eur.nl/pub/12738/Buitenhuis%20R%20351371.pdf (2012). Accessed September 22, 2014.
16. Decision Resources: European physician and payer forum. DPP-IV inhibitors and GLP-1 analogues for Type 2 diabetes—how are physician and payer perspectives shaping the European markets?
文摘
Introduction The objective of this study was to evaluate real-world treatment patterns of type 2 diabetes (T2D) patients initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Germany (GE), the United Kingdom (UK), France (FR), the Netherlands (NE), Belgium (BE), and Sweden (SE). Methods Adult T2D patients initiating exenatide twice daily (exBID), liraglutide once daily (LIRA) or exenatide once weekly (exQW) were identified using the IMS LifeLink?(IMS Health, Danbury, CT, USA): Electronic Medical Records (EMR; GE/UK/FR) and IMS LifeLink? longitudinal prescriptions (LRx; NE/BE/GE/UK) databases, and national health register data (SE), between 2010 and 2012. Therapy initiation date was termed ‘index date- Eligible patients had ?80-day pre- and variable follow-up (minimum ?60-day post-index exBID and LIRA, ?80-day post-index exQW). Treatment modification and persistence were evaluated over 180?days. Kaplan–Meier (KM) survival curves and Cox proportional hazards models (PHMs; EMR databases only) evaluated stopping of the index therapy (measured as first of discontinuation or switch). Results 30,206 exBID, 5,401 exQW, and 52,155 LIRA patients were included in the analysis (46.0-6.9% male; mean age range 55.4-9.3?years). Mean follow-up was 20.3-7.4?months for exBID and LIRA, and 7.6-3.9?months for exQW. Across the databases, the proportion experiencing a treatment modification at 180?days was highest among exBID (37.6-1.7%) compared to LIRA (36.8-6.6%) and exQW (32.3-7.7%). The proportion persistent at 180?days was lowest among exBID patients (46.8-3.5%) compared to LIRA (50.6-0.1%) or exQW (57.5-4.6%). In the KM analyses, LIRA patients had a lower proportion stopping therapy at all time points compared to exBID patients, across the databases. In the Cox PHMs, LIRA was associated with a significantly lower risk of stopping compared to exBID; in GE, exQW was associated with a lower risk compared to exBID and LIRA. Conclusion Treatment patterns varied among GLP-1 RA patients, with persistence highest among either LIRA or exQW across countries, and lowest among exBID. Longer-term data would be useful, particularly given limited exQW follow-up due to more recent launch.